Skip to content
Peptide research

NA-Semax Amidate

Also known as N-Acetyl Semax Amidate · Acetylated Semax
Category
Brain & Cognition
Administration routes
Nasal
Regulatory status
Not FDA-approved

A stabilized, injectable analog of Semax marketed for focus, cognitive enhancement, and stroke neuroprotection. Its best support comes from stroke recovery (improved outcomes with elevated BDNF), but claims about blood flow, brain connectivity, and memory gains rest on thin human data or mechanism studies alone. Safety data on this NA-Amidate form is essentially absent. Not an approved drug in the US; supply is largely unregulated research-grade peptide.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

NA-Semax Amidate (N-Acetyl Semax Amidate) is a chemically modified version of Semax, the nootropic and neuroprotective heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH 4-10) that retains the neurotropic activity of ACTH while lacking its hormonal (corticosteroid-stimulating) effects. The NA-Amidate modifications — N-acetylation and C-terminal amidation — enhance enzymatic stability and extend the functional half-life.

Semax has been extensively used in Russia since its approval for the treatment of stroke, traumatic brain injury, dyscirculatory encephalopathy, optic nerve atrophy, and cognitive disorders. Its mechanism of action is not fully elucidated but is thought to involve interaction with melanocortin receptors, inhibition of enkephalinase enzymes, increased BDNF and NGF expression, modulation of serotonin and dopamine levels, and enhancement of cerebral blood flow. Clinical studies in stroke patients have shown improved neurological outcomes and elevated plasma BDNF levels.

The N-acetyl and C-terminal amide modifications in NA-Semax Amidate serve the same purpose as in NA-Selank Amidate — protecting the peptide from N-terminal aminopeptidase and C-terminal carboxypeptidase degradation. The original Semax already includes a Pro-Gly-Pro extension at the C-terminus (compared to native ACTH 4-7) that enhanced its duration from minutes to 20-24 hours in animal models. The additional NA-Amidate modifications are expected to further improve metabolic stability, making this the most stabilized version of the Semax framework available.

How it works in the body

An N-acetylated, C-terminally amidated Semax analog with an unestablished pharmacological profile. Parent Semax studies suggest effects on neurotrophin signaling; they do not establish this analog's receptor targets, clinical benefits or hormonal safety.

Research overview

Semax (the parent compound) has a substantial Russian-language research base with approximately 100-200 PubMed-indexed publications. The ADDF Cognitive Vitality report states: 'Semax is used in Russia as a neuroprotective drug for stroke; however, there is little evidence whether it would improve cognition in healthy patients.' In Russian studies of stroke, intranasal Semax improved neurological function and increased plasma BDNF levels in 110 stroke patients (Gusev et al., 2018). For neuroprotection, Semax reduces infarction size and improves cognitive outcomes in rat models of photothrombosis (Romanova et al., 2006). For neurotrophins, intranasal Semax increases BDNF in the hippocampus (Dolotov et al., 2003) and BDNF/NGF in frontal cortex and hippocampus (Shadrina et al., 2010). For gene expression, Medvedeva et al. (2014) reported 96 altered genes at 3 hours and 68 at 24 hours in ischemic rat cortex after parent Semax. For cognitive effects, fMRI studies in healthy subjects show Semax (1.2mg intranasal) increases resting-state connectivity in the default mode network (Lebedeva et al., 2018). NA-Semax Amidate specifically has minimal published data; its use is based on the parent compound's profile plus expected benefits from peptide stabilization modifications.

Who researches NA-Semax Amidate?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Limited safety data on the specific NA-Amidate form

    High

    Absence of any indexed primary literature (PubMed search for NA-Semax / N-acetyl semax amide returns no relevant records)

  • Potential serotonergic and dopaminergic effects

    Low

    PMID 16362768; PMID 15088389

  • Methionine oxidation (specific to Semax/NA-Semax)

    Theoretical

    No primary study located; inference from methionine peptide chemistry

Interaction summary(6)

Rated by direction with this peptide

  • Amphetamines and dopaminergic psychostimulants (d-amphetamine, methylphenidate, ADHD medications)

    CautionLow

    In rodents Semax alone did not change dopamine levels but, given 20 min before d-amphetamine, dramatically enhanced amphetamine-evoked extracellular dopamine and locomotor activity. Because the described consequence is a larger-than-expected effect on arousal, focus and cardiovascular tone, this is an adverse-direction interaction, not a beneficial synergy. Severity is Low: the evidence is a single rodent study from one group, tested only with d-amphetamine (methylphenidate and other stimulants are extrapolation), and there are no human interaction data and none at all for the NA-amidate.

    PMID 16362768 (rodent, d-amphetamine only)

  • Opioids and opioid-peptide-modulating drugs

    CautionTheoretical

    PMID 11443939 (Bioorg Khim 2001) shows Semax and Selank inhibit enkephalin-degrading enzymes in human serum — but that is an in vitro serum-enzyme finding, not an in vivo or clinical one. Prolonged endogenous enkephalin signalling adding to opioid effects or altering tolerance dynamics remains a purely mechanistic inference; no in vivo, clinical, or NA-amidate data exist.

    PMID 11443939 (in vitro human serum enzyme inhibition)

  • SSRIs, SNRIs and other serotonergic agents

    CautionTheoretical

    Retained. Rodent work (PMID 15088389, and PMID 16362768 showing striatal 5-HIAA rising to ~180% extracellularly) shows Semax engages brain serotonergic systems, so additive serotonergic tone is conceivable when combined with reuptake inhibitors. Semax is not a known reuptake inhibitor or MAO substrate, and no case of serotonin syndrome or any human interaction has been reported — Theoretical is the correct ceiling.

    PMID 15088389; PMID 16362768

  • MAO inhibitors

    CautionTheoretical

    Purely mechanistic extension of the monoamine findings — if Semax amplifies stimulant-evoked catecholamine release, doing so against blocked monoamine breakdown is the least predictable combination; no study has tested it.

    PMID 16362768 (mechanistic basis only; no interaction study exists)

  • Standard acute ischemic stroke care (thrombolysis, antiplatelets, neurorehabilitation)

    SynergisticLow

    In Russian clinical use Semax was given as an add-on to standard stroke therapy and rehabilitation, with faster functional recovery and higher plasma BDNF and no reported interference with background treatment. However, these were unblinded, single-country studies not designed as interaction or co-administration safety studies, so 'no interference' is an absence of reported harm rather than a demonstrated safety finding; specifically, no study assessed co-administration with thrombolysis for bleeding risk. Nothing tested for the NA-amidate.

    PMID 29798983; PMID 11517472

  • Corticosteroids and the HPA axis (cortisol, ACTH-directed therapy)

    NeutralLow

    Semax is an ACTH(4-10)/ACTH(4-7)PGP analog that lacks the C-terminal steroidogenic portion of the ACTH sequence and is consistently described in the peptide literature as devoid of corticotropic activity, so meaningful interference with cortisol or steroid therapy is not expected. No dedicated endocrine interaction study exists for Semax, and none for the NA-amidate; this entry rests on structural reasoning about the ACTH fragment, not on a specific study.

    No primary source — structural/mechanistic inference from the ACTH(4-10) fragment lacking the steroidogenic region.

Known risks(3)

  • Limited safety data on the specific NA-Amidate form

    The parent compound Semax has a favorable safety profile from Russian clinical use, but the specific NA-Amidate modification has not been clinically tested. Safety is extrapolated from Semax data.

  • Potential serotonergic and dopaminergic effects

    Mild (theoretical)

    Semax increases serotonin levels and potentiates d-amphetamine effects on dopamine. Individuals on serotonergic or dopaminergic medications should exercise caution.

  • Methionine oxidation (specific to Semax/NA-Semax)

    Pharmacokinetic / Stability concern

    The N-terminal methionine in Semax is susceptible to oxidation, which can reduce potency. While N-acetylation may partially protect against this, proper storage (refrigeration, protection from light) is important.

Drug interactions(4)

  • SSRIs and serotonergic medications

    Semax increases serotonin levels in the brain. Combining with SSRIs or other serotonergic drugs could produce additive serotonergic effects. Monitor for signs of serotonin excess.

  • Psychostimulants (amphetamines, methylphenidate)

    Semax has been shown to potentiate the dopaminergic effects of d-amphetamine in preclinical studies. Combining with stimulants could increase cardiovascular and neuropsychiatric effects.

  • Anticoagulants and antiplatelet agents

    Semax affects vascular gene expression and has been studied in stroke. Theoretical interactions with blood-thinning medications are possible. Clinical significance is unknown.

  • Corticosteroids (prednisone, dexamethasone)

    As an ACTH fragment derivative, Semax could theoretically interact with corticosteroid signaling, though it lacks direct adrenal-stimulating activity. The interaction is unlikely to be clinically significant.

Research & benefits

Evidence base

Evidence Level
Very Limited Evidence
Total Studies
150
Human Studies
0 participants in identified clinical studies of NA-Semax Amidate.

Semax has been used clinically in Russia for over two decades for stroke, TBI, and cognitive disorders. However, most clinical data is published in Russian-language journals with limited English translations. Key clinical findings include improved neurological outcomes in stroke patients (n=110) and increased BDNF levels. An fMRI study in healthy subjects showed neural connectivity changes with intranasal Semax. The ADDF notes that 'published literature of well-conducted studies is lacking' in English. NA-Semax Amidate has not been tested in clinical trials.

Researched for(6)

Rated by confidence in the evidence

  • Neuroprotection in stroke — improved outcomes and elevated BDNF in clinical use

    Medium

    Small, unblinded human trials in stroke patients reported faster recovery and raised BDNF.

    PMID 29798983; PMID 11517472; PMID 10358912

  • Increased BDNF and NGF expression in hippocampus and frontal cortex

    Medium

    Extensive animal data, mostly one research lineage, with supportive human plasma BDNF findings.

    PMID 16996037; PMID 19662538; PMID 17353092; PMID 18756821; PMID 19633950

  • Default mode network changes reported with parent Semax; benefit for NA-Semax Amidate is unestablished

    Speculative

    DMN connectivity shifts were shown for parent compound Semax, not tested directly in NA-Semax Amidate.

    PMID 30225715 (Lebedeva et al. 2018, human fMRI, n=24, placebo-controlled, tested Semax); PMID 32342318 (Panikratova et al. 2020, human connectomic fMRI, n=52, tested Semax and Selank). Neither trial administered NA-Semax Amidate. No primary source supports a cerebral blood flow or microcirculation effect for either compound.

  • Broad gene expression changes in immune, vascular, and neurotrophin pathways

    Low

    Extensive rodent gene-expression data from one research group; not a clinical outcome measure.

    PMID 24661604; PMID 28255762; PMID 34201112; PMID 19633950; PMID 32580520

  • Enhanced metabolic stability compared to parent Semax (N-acetyl + amide modifications)

    Speculative

    No direct studies exist; stability inferred from peptide chemistry principles alone.

    PMID 16637290 (tritium-labelled peptide biodegradation, indirect support for rapid parent-Semax degradation); no primary source exists for the NA-amidate form

  • Cognitive enhancement — improved attention and short-term memory

    Low

    Human EEG study suggests attention effects; no controlled trials confirm cognitive benefits.

    PMID 8679991 (human EEG). Rodent cognitive-outcome evidence: no primary source.

Benefits(6)

  • Neuroprotection in stroke — improved outcomes and elevated BDNF in clinical use

    Gusev et al., 2018 (n=110 stroke patients, parent Semax, Russian; PMID 29798983); Gusev et al., 1997

  • Increased BDNF and NGF expression in hippocampus and frontal cortex

    Dolotov et al. 2003, 2006; Shadrina et al. 2010 (all Semax, rat models)

  • Default mode network changes reported with parent Semax; benefit for NA-Semax Amidate is unestablished

    Lebedeva et al. 2018 (n=24, healthy subjects, fMRI, Semax intranasal)

  • Broad gene expression changes in immune, vascular, and neurotrophin pathways

    Kolomin et al., PMC 2014 (microarray analysis of Semax effects on rat brain)

  • Enhanced metabolic stability compared to parent Semax (N-acetyl + amide modifications)

    General peptide medicinal chemistry; specific comparison data limited

  • Cognitive enhancement — improved attention and short-term memory

    Eremin et al., Russian study in healthy volunteers (Semax, 250-1000 mcg/kg)

Key studies(3)

  1. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia

    Preclinical (genomic analysis, focal ischemia model)Rat brain tissue, genome-wide expression3 and 24 hours after ischemia, with parent Semax treatment

    Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV

    BMC Genomics (PMC)

    2014

    Parent Semax altered 96 genes at 3 hours and 68 at 24 hours versus ischemia controls, particularly immune- and vascular-related genes.

  2. Alzheimer's Drug Discovery Foundation (ADDF)

    Cognitive Vitality Reports

    2020

    Independent assessment: Semax may be beneficial in stroke patients and is used clinically in Russia, but English-language literature of well-conducted studies is lacking. Semax increases BDNF in hippocampus and cortex. Little evidence exists for cognitive benefit in healthy individuals or for Alzheimer's disease.

  3. Multiple contributors

    Wikipedia

    2024

    Semax is a heptapeptide ACTH 4-10 analog used in Russia for stroke, TBI, cognitive disorders, and optic nerve atrophy. Mechanism involves melanocortin receptors, enkephalinase inhibition, and neurotrophin upregulation. ATC code N06BX.

Regulation & availability

Why researchers look at it

NA-Semax Amidate is a stabilized modification of Semax, a neuroprotective peptide used in Russia for stroke and brain injury for over two decades. Its proposed benefits are extrapolated from parent Semax. Neurotrophin effects, blood-flow improvement, cognitive benefit and hormonal safety have not been established for this analog.

FDA status
Not FDA-Approved. Neither NA-Semax Amidate nor the parent compound Semax has FDA approval. Semax is approved as a prescription medication in Russia (nasal spray) and Ukraine for stroke, TBI, cognitive disorders, and optic nerve atrophy. It holds the ATC code N06BX (other psychostimulants and nootropics). No IND applications are publicly known in the United States. NA-Semax Amidate is not covered by the draft interim compounding policy HHS posted on October 28, 2026, which names only semax free base for nasal use.
WADA status
NA-Semax Amidate is not individually named on the 2026 WADA Prohibited List. If it lacks current governmental approval anywhere for human therapeutic use and is not covered elsewhere on the List, S0 prohibits it at all times. Parent Semax's registration does not establish approval of this analog.
Prescribability
No — Not FDA-approved. Parent compound Semax approved in Russia and Ukraine.
Availability
No pharmaceutical approval was identified for NA-Semax Amidate in any country. Russian registration concerns parent Semax, which is available as a prescription nasal spray (0.1% and 1% solutions) in Russia and Ukraine and can be obtained from Russian pharmacies. The 0.1% solution is used for cognitive enhancement while the 1% solution is used for stroke treatment.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(7)

  1. 1950s
    Discovery that ACTH has cognitive effects beyond hormonal function
  2. 1970s
    Pro-Gly-Pro C-terminal extension developed to stabilize ACTH fragments
  3. 1990s
    Semax developed and approved in Russia for neurological conditions
  4. 2006
    Semax shown to increase BDNF in rat hippocampus (Dolotov et al.)
  5. 2014
    Genome-wide expression analysis of Semax effects in ischemic brain published in PMC
  6. 2018
    Clinical study shows Semax elevates BDNF in stroke patients (n=110)
  7. 2018
    fMRI study demonstrates Semax effects on brain connectivity in healthy subjects

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

What do the 'NA' and 'Amidate' modifications do compared to regular Semax?

N-Acetylation (NA) protects the methionine N-terminus from aminopeptidase degradation, while C-terminal amidation protects against carboxypeptidase cleavage. Original Semax already has enhanced stability from its Pro-Gly-Pro tail (extending activity to 20-24 hours vs minutes for ACTH fragments). The NA-Amidate modifications are expected to further improve stability, potentially enabling lower or less frequent dosing.

How is Semax related to ACTH?

Semax is based on the ACTH(4-10) fragment — the portion of adrenocorticotropic hormone that retains neurotropic (brain-protective) activity but lacks the adrenal-stimulating hormonal effects of full ACTH. The Pro-Gly-Pro tail was added to the C-terminus to extend the very short half-life of the native ACTH fragment from minutes to many hours.

What conditions is Semax used for in Russia?

In Russia, Semax is prescribed for: ischemic stroke (acute and recovery), dyscirculatory encephalopathy, traumatic brain injury recovery, optic nerve atrophy, cognitive disorders, and as a general neuroprotective agent. The 0.1% nasal spray is used for cognitive conditions while the 1% solution is used for stroke and severe neurological conditions.

Does NA-Semax Amidate have hormonal effects like ACTH?

Parent Semax is described as lacking ACTH-like hormonal activity: the key achievement in developing Semax from ACTH was eliminating the hormonal activity while preserving the neurotrophic effects, and the ACTH(4-10) fragment does not stimulate cortisol production or affect the adrenal glands. That does not establish the hormonal effects or safety of NA-Semax Amidate.